InDex Pharmaceuticals Holding Management
Management criteria checks 2/4
InDex Pharmaceuticals Holding's CEO is Jenny Sundqvist, appointed in Jan 2023, has a tenure of 1.33 years. total yearly compensation is SEK3.54M, comprised of 64% salary and 36% bonuses, including company stock and options. directly owns 0.023% of the company’s shares, worth SEK61.70K. The average tenure of the management team and the board of directors is 4.5 years and 8.3 years respectively.
Key information
Jenny Sundqvist
Chief executive officer
kr3.5m
Total compensation
| CEO salary percentage | 64.0% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.02% |
| Management average tenure | 4.5yrs |
| Board average tenure | 8.3yrs |
Recent management updates
Recent updates
Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce
Apr 28
We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate
Jul 11We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Jan 21We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth
Aug 31Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation
Mar 29InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.
Feb 04
How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?
Dec 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -kr56m |
| Dec 31 2023 | kr4m | kr2m | -kr95m |
Compensation vs Market: Jenny's total compensation ($USD332.27K) is above average for companies of similar size in the Swedish market ($USD253.80K).
Compensation vs Earnings: Insufficient data to compare Jenny's compensation with company performance.
CEO
Jenny Sundqvist (52 yo)
1.3yrs
Tenure
kr3,543,000
Compensation
Ms. Jenny Sundqvist serves as Chief Executive Officer of InDex Pharmaceuticals Holding AB (publ) since January 01, 2023. She served as Chief Commercial Officer of Isofol Medical AB (publ) from January 1, 2...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 1.3yrs | kr3.54m | 0.023% SEK 61.7k | |
| Deputy CEO & Chief Financial Officer | 7yrs | kr2.80m | 0.073% SEK 197.3k | |
| Chief Scientific Officer | 2yrs | no data | 0.0017% SEK 4.6k | |
| Head of Regulatory Affairs | 11.3yrs | no data | no data |
4.5yrs
Average Tenure
55yo
Average Age
Experienced Management: INDEX's management team is considered experienced (4.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 13.3yrs | kr235.00k | 0.081% SEK 218.6k | |
| Independent Director | 8.3yrs | kr235.00k | 0.077% SEK 206.4k | |
| Director | no data | no data | no data | |
| Member of Advisory Board - North America | no data | no data | no data | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Independent Chairman | 13.3yrs | kr500.00k | 0.14% SEK 382.4k | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Chairman of Advisory Board - Europe | 1.9yrs | no data | no data | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Member of Advisory Board - Europe | no data | no data | no data | |
| Member of Advisory Board - North America | no data | no data | no data |
8.3yrs
Average Tenure
69yo
Average Age
Experienced Board: INDEX's board of directors are considered experienced (8.3 years average tenure).